Ionis Pharmaceuticals (IONS) Revenue (2009 - 2026)

Ionis Pharmaceuticals' Revenue history runs 18 years deep, the most recent figure standing at $246.1 million for Q1 2026.

• On a quarterly basis, Revenue rose 86.98% year-over-year to $246.1 million in Q1 2026; TTM through Mar 2026 was $608.1 million, a 15.21% decrease from a year earlier, with the FY2025 full-year figure at $943.7 million, up 33.83% from the prior year.
• Revenue rose to $246.1 million in Q1 2026 per IONS's latest filing, from $203.3 million in the prior quarter.
• Across five years, Revenue topped out at $324.5 million in Q4 2023 and bottomed at $2.0 million in Q2 2025.
• The 5-year median for Revenue is $151.9 million (2022), against an average of $165.9 million.
• Across the five-year window, Revenue surged 113.64% in 2023 and slumped 99.11% in 2025, its largest moves.
• Year by year, Revenue stood at $151.9 million in 2022, then soared by 113.64% to $324.5 million in 2023, then plunged by 30.18% to $226.6 million in 2024, then declined by 10.26% to $203.3 million in 2025, then advanced by 21.03% to $246.1 million in 2026.
• Per Business Quant, the three latest IONS Revenue figures stand at $246.1 million (Q1 2026), $203.3 million (Q4 2025), and $156.7 million (Q3 2025).